Dean Elterman, MD, on tailoring BPH MIST therapies for the individual patient

In this interview, Dean S. Elterman, MD, MSc, FRCSC, gives an overview of his 2025 Desai Sethi Urology Institute Urology on the Beach meeting talk, "Tailoring MIST therapies in BPH for the individual." Elterman is an associate professor of urology at the University of Toronto in Ontario, Canada.

Transcription:

Please provide an overview of your 2025 Urology on the Beach talk "Tailoring MIST therapies in BPH for the individual."

This year, at the Urology on the Beach conference, I spoke about the various types of new BPH technologies and how we can really pick and choose them based upon a number of criteria. We know that a lot of men are dissatisfied with medical therapy or don't want to take medical therapy, so there's really been this birth of these minimally invasive surgical therapies, or MISTs. In the United States, we have Rezum, UroLift, Optilume BPH, and iTind, and of course, it's picking and choosing which patients should either get a MIST or not get a MIST, and then which of the 4 options available we should try to tailor to each individual man. That's the overall concept of it. I think when we get into it a little bit deeper, it has a lot to do with taking into consideration patient factors, prostate factors—size, volume, whether they have a median lobe—and then also personal preferences and values. A lot of shared decision-making has to do with, what is important to the individual man? Is it recovery? Is it side effect profile? Is it preserving sexual function? All of these things really go into tailoring the experience and tailoring the treatment.

This transcript was AI generated and edited by human editors for clarity.